INTRODUCTION {#sec1-1}
============

Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, leading to shortness of breath, dizziness, fainting, and other symptoms, all of which are exacerbated by exertion. PH in pregnancy carries a 25--56% maternal mortality rate with a mixture of intrapartum and postpartum deaths.\[[@ref1][@ref2][@ref3]\] The published literature contains no large prospective studies comparing outcomes with regard to the relevant clinical questions. There is no consensus on the gold standard management of PH in parturient with regards to timing of delivery, choice of delivery technique and anesthetic choice. The current literature consists of a few case reports, a few small case series (\<15) and 2 meta-analyses.

This article describes the experiences and outcomes of 19 deliveries occurring over a 15-year period at a tertiary center for obstetrics, cardiology and neonatology. The organization has a high-risk obstetric service making use of these and other specialty services as required.

MATERIALS AND METHODS {#sec1-2}
=====================

A review of all patients admitted to our institution for management of PH in pregnancy between 1994 and February 2009 was undertaken. Institutional ethics approval was obtained for the study. Cases were identified from the high-risk pregnancy database within the department of anesthesia and from the hospital medical records. Maternal admissions with coded co-morbidities of PH, primary PH and secondary PH were identified. Demographic data were recorded. Severity of PH were based on systolic pulmonary artery pressure (sPAP) estimation on transthoracic echocardiogram (TTE) and classified as mild (30--40 mmHg), moderate (40--70 mmHg) or severe (\>70 mmHg). Other parameters noted were the type of PH (primary or secondary), New York Heart Association (NYHA) functional status at presentation, NYHA at delivery, timing of delivery (weeks), mode of delivery, peripartum monitoring used for anesthetic management, oxytocin dose given, APGAR scores at 1 and 5 min and birth weight \[[Table 1](#T1){ref-type="table"}\].

###### 

Age, gravidity, cause and severity of PH, NYHA class, timing and mode of delivery, monitors used and neonatal outcomes

  Case number   Age   \(G\) Gravidity (P) Parity   Cause of PH                             NYHA presentation   NYHA at delivery   PH grade at presentation   Timing of delivery (weeks)   Mode of delivery   Peripartum monitors     Oxytocin dose   Neonatal outcome         
  ------------- ----- ---------------------------- --------------------------------------- ------------------- ------------------ -------------------------- ---------------------------- ------------------ ----------------------- --------------- ------------------ ----- ------
  1             32    G2P1                         Secundum ASD                            I                   I                  Moderate                   38                           Elective LUSCS     Arterial catheter       2.5             7                  9     3265
  2             25    G3P2                         MV and coarctation repair               I                   I                  Moderate                   38                           Unassisted NVD     Arterial catheter PAC   5               9                  9     3040
  3             37    G2P1                         ASD, VSD, Eisenmenger's                 IV                  IV                 Severe                     35                           Emergency LUSCS    Arterial catheter       10              9                  9     1950
  4             32    G7P3                         TR                                      II                  II                 Mild                       36                           Unassisted NVD     Arterial catheter PAC   5               8                  9     2792
  5             39    G10P7                        TR                                      III-IV              III                Severe                     37                           Unassisted NVD     Arterial catheter CVC   2.5             8                  9     3540
  6             29    G2P1                         Mixed rheumatic MV disease              II                  I                  Moderate                   39                           Elective LUSCS     Arterial catheter       2.5             8                  10    3810
  7             30    G3P2                         Mixed rheumatic MV disease              IV                  II                 Moderate                   38                           Unassisted NVD     Noninvasive             5               8                  9     2875
  8             33    G1P0                         Mixed rheumatic MV disease              IV                  I                  Moderate                   40                           Instrumented VD    Noninvasive             10              9                  10    3715
  9             37    G3P2                         Mixed rheumatic MV disease              III                 III                Mild                       35                           Elective LUSCS     Arterial catheter TOE   5               3                  5     2484
  10            30    G1P0                         PPH                                     II                  II                 Severe                     34                           Elective LUSCS     Arterial catheter PAC   0.8             4                  8     1748
  11a           31    G3P1                         VSD                                     II                  II                 Moderate                   31                           Elective LUSCS     Arterial catheter PAC   4.5             9                  10    2885
  lib           32    G4P2                         VSD                                     II                  II                 Severe                     32                           Elective LUSCS     Arterial catheter PAC   10              7                  8     N/A
  12a           25    G3P1                         Rheumatic mitral stenosis               II                  I                  Severe                     25                           Unassisted NVD     Arterial catheter PAC   N/A             8                  9     2875
  12b           34    G4P2                         Rheumatic mitral stenosis               IV                  IV                 Severe                     34                           Emergency LUSCS    Arterial catheter PAC   N/A             N/A                N/A   N/A
  13            26    G1P0                         Mixed rheumatic MV disease and AI       I                   I                  Moderate                   26                           Elective LUSCS     Arterial catheter PAC   2               9                  9     2713
  14            30    G3P2                         Mixed rheumatic MV disease              IV                  IV                 Moderate                   30                           Emergency LUSCS    Arterial catheter       5               7                  9     2610
  15            27    G1P0                         Corrected TOF, severe PR, moderate TR   II                  II                 Moderate                   27                           Instrumented VD    Noninvasive             2.5             9                  9     2900
  16            36    G3P2                         Mixed rheumatic MV disease              I                   I                  Moderate                   36                           Unassisted NVD     Noninvasive             10              9                  9     3130
  17            37    G2P1                         PPH                                     I                   I                  Moderate                   37                           Elective LUSCS     Noninvasive             10              3                  7     3030

NYHA: New York Heart Association, PH: Pulmonary hypertension, PPH: Primary pulmonary hypertension, MV: Mitral valve, TR: Tricuspid regurgitation, ASD: Atrial septal defect, VSD: Ventricular septal defect, TOF: Tetralogy of fallot, PR: Pulmonary regurgitation, LUSCS: Lower uterine segment cesarean section, NVD: Normal vaginal delivery, VD: Vaginal delivery, PAC: Pulmonary artery catheter, CVC: Central venous catheter, TOE: Transesophageal echocardiogram, N/A: Not available

All patients with PH were seen in the high-risk obstetrics clinic at 25 weeks, except for one patient who presented in late pregnancy. Patients were jointly reviewed by obstetricians, cardiologists, intensive care physicians and anesthetists. A standard and emergency medical management plan was developed for each patient, including details of the proposed delivery methods, timing and medical therapy required in the peripartum period.

RESULTS {#sec1-3}
=======

Twenty-two cases were identified. Two had PH diagnosed on TTE in the setting of acute reversible pulmonary pathology. In both cases, subsequent TTE confirmed reversion to normal sPAP prior to delivery and these patients were excluded from this review. A further patient had pulmonary stenosis with elevated right ventricular systolic pressures but no pulmonary vascular hypertension and was therefore also excluded. Of the remaining 19 cases, two were second pregnancies and considered as separate events \[[Table 1](#T1){ref-type="table"}\]. Six of these had severe, 11 had moderate, and two had mild PH at presentation \[[Table 1](#T1){ref-type="table"}\]. One of these mothers presented in extremis with cardiac failure in late pregnancy with no antenatal care. Emergency cesarean section was undertaken. Both mother and baby died in the days following delivery. Neonatal outcomes are detailed by etiology in [Table 2](#T2){ref-type="table"}.

###### 

Neonatal outcomes in relation to etiology

                     Mean maternal age   Means PAP   Mean 1-min APGAR   Major morbidity   GA/RA   Vag/LUSCS   Mean birth weight
  ------------------ ------------------- ----------- ------------------ ----------------- ------- ----------- -------------------
  Primary PH: 2      34.5                87          6                  50                1/1     1/1         2644
  CHD: 4             31.75               67.5        8.5                25                2/2     1/3         1934
  Secondary PH: 13   31.23               60.38       6.77               23                2/11    6/7         2795
  Mean               31.68               64.68       7.05               32                5/14    8/11        2598

PAP: Pulmonary artery pressure, GA: General anesthesia, RA: Regional anesthesia, LUSCS: Lower uterine segment cesarean section, PH: Pulmonary hypertension, CHD: Congenital heart disease

Major morbidity was classified as cardiac, respiratory or renal failure, and occurred in four of the remaining 18 patients. The morbidity was all in mothers with more significant disease, which also had a greater effect on the fetus \[[Table 3](#T3){ref-type="table"}\]. The most common morbidity was cardiac failure, occurring in three patients with severe PH secondary to mitral stenosis. These patients were initially managed with medical therapy but subsequently required percutaneous mitral valvuloplasty. All mothers achieved significant reductions in sPAP postvalvuloplasty prior to delivery. There were no infant or maternal deaths in these patients. In our series, severity of PH and morbidity also appeared to increase with maternal age as shown in [Table 4](#T4){ref-type="table"}. Mode of delivery and anesthetic technique in relation to the severity of PH is shown in [Table 5](#T5){ref-type="table"}.

###### 

Neonatal outcomes in relation to severity of PH

  sPAP                       Median neonatal 1 min APGAR   Mean birth weight
  -------------------------- ----------------------------- -------------------
  Mild PH (sPAP \<40)        8                             3098.33
  Moderate PH (sPAP 40-70)   8                             2973.33
  Severe PH (sPAP \>70)      6                             2222.70

PH: Pulmonary hypertension, sPAP: Systolic pulmonary artery pressure

###### 

Relation of maternal age, severity of PH and maternal morbidity

  Maternal age   Mild PH   Moderate PH   Severe PH   Maternal morbidity   Median neonatal 1-min APGAR   sPAP
  -------------- --------- ------------- ----------- -------------------- ----------------------------- -------
  20-25          0         1             1           1/2                  8.5                           73
  26-30          0         5             1           0/6                  7.5                           59.17
  31-35          1         3             2           1/6                  8                             62.16
  36-40          1         2             2           3/5                  6.4                           71

PH: Pulmonary hypertension, sPAP: Systolic pulmonary artery pressure

###### 

Mode of delivery and anesthetic technique in relation to severity of PH

                Vaginal delivery   Emergency LUSCS   Elective LUSCS   GA   RA
  ------------- ------------------ ----------------- ---------------- ---- ----
  Mild PH       1                  0                 1                1    1
  Moderate PH   5                  1                 5                0    11
  Severe PH     2                  2                 2                4    2

PH: Pulmonary hypertension, GA: General anesthesia, RA: Regional anesthesia; LUSCS: Lower uterine segment cesarean section

At presentation, five out of 19 patients had NYHA functional status I, seven were NYHA II, one patient met criteria for NYHA III and six patients were classified as NYHA IV. At the time of delivery, there was an overall improvement in functional status: Eight were NYHA I, six were NYHA II, two were NYHA III, and three were NYHA IV.

DISCUSSION {#sec1-4}
==========

Clinical classification of PH has been updated in 2008 and divided into five groups by world health organization. Broadly, pulmonary arterial hypertension (Group 1), pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis (Group 1'), PH due to left heart disease (Group 2), PH due to lung diseases and/or hypoxia (Group 3), Chronic thromboembolic PH (Group 4), and PH with unclear and/or multifactorial mechanisms (Group 5).\[[@ref4]\] However, many of the articles quoted have been published prior to this new classification, and we have used the term primary PH (idiopathic under new classification) and secondary PH in this article. Mortality in pregnant women with PH is high, with rates quoted as 30% for primary PH, 36% for Eisenmenger\'s syndrome and 50% for secondary PH.\[[@ref1]\] However, a systematic outcome review of PH in pregnancy was compared between 2-time periods, 1978--1996 and 1997--2007. Results showed a significant decline in maternal mortality from 38% to 25% during the period 1997--2007 suggesting advanced therapies and a multidisciplinary approach may have produced better outcomes.\[[@ref3]\] Our series has a mortality rate of 5%, with the only death being of a patient who died following delivery from cardiac failure due to fulminant and previously unrecognized PH, having undergone no antenatal assessment or care. Current recommendations for management of PH in pregnancy include termination of pregnancy if diagnosed early\[[@ref1]\] or utilizing a controlled interventional approach with early nebulized prostanoid therapy and early elective cesarean section under regional anesthesia.\[[@ref2]\] Other recommended therapies for peripartum management of PH include sildenafil and nitric oxide.\[[@ref3]\]

Disease severity {#sec2-1}
----------------

Functional classification has been found to have a high correlation with prognosis in pregnant patients with PH and with mitral valve disease,\[[@ref5][@ref6][@ref7][@ref8]\] and it is the patients' exercise tolerance that primarily directs clinical management. Many patients with severe disease cope well in their day to day lives and report little in the way of symptoms. When they do complain, symptoms are often nonspecific. Of greatest concern is progressive breathlessness or extreme, but general tiredness, which are often attributed to the pregnant state by both patients and their carers. In our series, there was poor correlation in severity of PH and NYHA status, that is, patients with NYHA IV were not always severe PH, likewise NYHA I patients did not necessarily confer mild PH.

In this series, TTE was used to confirm PH. Although cardiac catheterization remains the gold standard for diagnosis of PH, except in pregnancy, it carries a 1--5% risk of serious complication,\[[@ref9]\] which may be increased in the critically ill obstetric patient.\[[@ref10]\] Conflicting reports exist as to the accuracy of TTE in estimating PAP in pregnancy. A retrospective review found that TTE overestimates PAP in pregnancy.\[[@ref9]\] This overestimation was found to be greater in patients with structural cardiac defects.\[[@ref9]\] Conversely, a prospective study where TTE and pulmonary artery catheter (PAC) measurements were done simultaneously found no difference between the two measurements.\[[@ref10]\] The severity of PH on TTE and clinical condition of the patient directed the obstetric and anesthetic decisions. Our patients were monitored with TTE for progression in severity of PH and assessment of right heart function. The decision to use TTE for clinical management, rather than the NYHA status, is based in a belief that TTE changes will predate functional decline. This hypothesis forms the basis of our management but is yet to be tested in pregnancy. TTE assessments need to be made in the knowledge that cardiac output (CO) and pulmonary resistance determine PAPs. Hence, in pregnancy with increasing CO, we may see an increase in the pressure but the underlying resistance may not have changed.

One of our patients with moderate PH on TTE who denied symptoms underwent exercise echocardiography during the first trimester of her pregnancy. Ventricular function was in the low normal range at rest, but exercise-induced marked hypokinesis, without any symptoms. At 32 weeks, her resting pulmonary pressures were noted to be in the severe range, hence delivery was thought prudent. She went on to have an uneventful cesarean section under GA and recovery. Exercise echocardiography may be a useful way of "stress testing" pregnant women with PH to assess their reserve and direct delivery timing.

Disease etiology {#sec2-2}
----------------

The underlying etiology identifies patients at the highest risk of acute cardiac decompensation during pregnancy. The existing body of literature suggests that secondary PH has the highest risk of mortality\[[@ref11]\] and that PH secondary to mitral valve stenosis poses a high risk of acute pulmonary edema as the pregnancy progresses. Mortality is 1% for NYHA classes II and I and increases to 5% for NYHA classes III and IV.\[[@ref5][@ref6][@ref7]\] In the presence of atrial fibrillation, the mortality increases to 14--15%.\[[@ref6][@ref7]\] There is a higher fetal and neonatal complication rate in women with a history of cardiac events or symptoms prior to pregnancy.\[[@ref6][@ref7]\] The risk is greatest near term and in the peripartum period.\[[@ref5][@ref6]\] Intensive medical management of patients with developing heart failure is successful in stabilizing most symptomatic patients\[[@ref7][@ref12]\] and allows many to continue the pregnancy to term and improves maternal condition for delivery.\[[@ref12]\] Percutaneous mitral valvuloplasty should be considered if cardiac performance deteriorates.\[[@ref13]\]

Eight patients in this series had significant rheumatic mitral stenosis, one of whom had two pregnancies. Four of these required medical management in order to stabilize symptoms, in the form of diuretics, digitalis, anticoagulation and nifedipine. Three of these four patients then underwent mitral valvuloplasty and had immediate improvement in symptoms. One was discharged at 31 weeks and represented in spontaneous labor at 40 weeks. She went on to have an uncomplicated delivery. A second had a more complicated course suffering pericardial tamponade during the procedure, which was successfully drained with a pericardial catheter. After a few days of improvement in her symptoms, she developed rapid atrial fibrillation and subsequently underwent urgent cesarean section. The last presented with two pregnancies, had the valvotomy during the first and uneventfully delivered vaginally 12 weeks after the procedure. During her second pregnancy, she presented at 36 weeks with pneumonia and acute pulmonary edema, threatened respiratory arrest that necessitated emergency cesarean section. She subsequently made a good recovery. Nitric Oxide was used in one patient who then received sildenafil in the postoperative period.

Timing and mode of delivery {#sec2-3}
---------------------------

Patient management aims at supporting pregnancy for as long as possible toward term for a normal vaginal delivery. Cesarean section may have the potential for greater hemodynamic instability due to blood loss and pain. Operative delivery has been found to be an independent risk factor for maternal mortality in patients with secondary PH and a potential risk factor for all patients.\[[@ref1]\] The optimal mode of delivery remains controversial; however, a recent paper suggested that a planned cesarean section at 34 weeks under regional anesthesia was their preferred approach.\[[@ref14]\] At our institution, if patients remained well, the pregnancy was allowed to continue, albeit with frequent review with vaginal delivery as the preferred mode. However, Cesarean section was not an infrequent occurrence often due to obstetric indications, emergency presentations and failure of medical management. Any sign of breathlessness or generalized tiredness would prompt hospital admission and delivery if symptoms did not resolve with bed rest and medical management. Additionally, signs of right heart failure would necessitate urgent cesarean section. In this series, 8 vaginal deliveries were achieved. Those with moderate to severe disease labored in the intensive care unit (two patients) or coronary care (two patients) with both a midwife and intensive care nurse in attendance. This facilitated both obstetric care and intensive monitoring of the hemodynamic parameters of the mothers. The first 72 h postpartum appears to be the time of greatest risk, when the hemodynamic changes reach their peak, with most maternal deaths occurring early after delivery.\[[@ref1][@ref11][@ref15][@ref16]\] It is, therefore, important that these patients remain in a monitored environment after delivery, where they can be observed intensively and have appropriate intervention should the need arise.

One emergency and two elective cesarean sections were performed for obstetric indications (breech, previous cesarean). Two emergency cesarean sections were performed for acute heart failure. Five cesarean sections were performed due to concern about the mother\'s cardiac condition. It has been suggested that vaginal delivery is better tolerated than cesarean delivery by pregnant women with PH\[[@ref11][@ref17]\] or it may be that the women allowed to labor have less severe disease and, therefore, better outcomes.

Labor analgesia {#sec2-4}
---------------

For labor, epidural analgesia is the preferred option. It is titratable and minimizes the hemodynamic effects of pain. All patients who had vaginal deliveries had pain relief with epidural analgesia without any complications. Theoretically, the systemic vasodilatation produced by the sympathetic block may induce hypotension in the patient with a limited or fixed return to the left atrium, but this has not been a problem in our series of laboring woman, probably due to the slow onset of the block allowing compensation. There were no complications related to the use of epidural analgesia in this series.

Cesarean section and anesthetic choice {#sec2-5}
--------------------------------------

This decision was dictated by the managing anesthetist based on the severity of PH. The ability of the patient to lie flat may often be the deciding factor between a regional and general anesthesia (GA) for cesarean section. In this series, 5 out of 10 cesarean sections were performed under epidural anesthesia. Five patients underwent cesarean section under GA. In one, regional anesthesia was contraindicated due to anticoagulation and maternal hemodynamic instability. In another two, maternal instability precluded regional anesthesia. In one case, GA was administered to better control the use of nitric oxide that was deemed necessary due to severe disease. In all cases, good neonatal and maternal outcomes were achieved.

General anesthetic technique {#sec2-6}
----------------------------

This varied with anesthetist, but the commonest practice was to use a small dose of midazolam to allay the anxiety associated with placement of invasive lines, cognizant of the fact that sedation may worsen pulmonary vascular resistance. Preoxygenation was administered via facemask. Induction was achieved using 3--5 mcg/kg of fentanyl to provide stable hemodynamics and good modification of the hemodynamic response to laryngoscopy supplemented with judicious doses of propofol as required. Standard inhalational anesthetic technique, with O~2~ in air and isoflurane or sevoflurane, was used for maintenance.

Maintenance of ideal homeostasis is important. Temperature, acid-base balance, oxygenation and carbon dioxide levels should all be maintained within the normal range and deviation can have quite profound effects on the pulmonary pressure. A large alveolar-arterial CO~2~ gradient was often observed, and a blood gas should be checked early on and ventilation adjusted accordingly.

One patient undergoing GA received inhaled nitric oxide intraoperatively. This improved both the hemodynamics and the blood gases. Nebulized prostacyclin is now available in our institution and has the advantage of being much easier to use while still being effective. It is categorized as B3: Drugs, which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

However, Kiely *et al*. reported use of prastanoid therapy without harmful effects to the fetus.\[[@ref14]\] Prostacyclin derivatives, endothelin receptor antagonists, and phosphodiestarase-5 inhibitors have been approved for use in PH. However, these agents are not approved for the treatment of PH associated with sickle cell disease due to inadequate data to support their efficacy.\[[@ref18]\] It is often necessary to support the systemic circulation whilst using nitric oxide and in this case noradrenalin was used and found it to be effective. Adrenaline also has been reported to be useful, although we are concerned about the potential for tachycardia.

Use of oxytocin {#sec2-7}
---------------

Bolus doses of oxytocin cause hypotension via systemic vasodilatation, and this effect is exaggerated in the anaesthetized patient. This can exacerbate PH by reducing right coronary blood flow leading to right ventricular failure and a low output state that is not responsive to volume or inotropic support. Although induction or augmentation of labor with low-dose oxytocin is considered safe, there have been reports of exacerbation of primary PH at low infusion rates.\[[@ref17][@ref19]\] Ergometrine and prostaglandin F2 alpha cause pulmonary vasoconstriction and therefore contraindicated in PH.\[[@ref19]\]

In this series, six patients underwent augmentation of labor with low dose intravenous (IV) oxytocin. A bolus of oxytocin was given in all but two cases (both the same patient), in doses ranging from 0.8 units to 10 units IV. The one patient in our series who received 10 units of oxytocin was the one who underwent cesarean section prior to the diagnosis of severe PH. This dose was the routine practice at the time. There were no adverse hemodynamic effects documented in the other patients, which may be due to the smaller doses given and the longer administration times.

Monitors {#sec2-8}
--------

In the literature, the use of PAC is controversial with little evidence of an improvement in outcome. Nonetheless, they are often used because they offer parameters on which clinical decisions are made in a group of patients in whom assessment can be difficult. In particular, the use of pulmonary vasodilating drugs requires quantified parameters to guide their use. In our institution, we use PAC catheters for those with severe disease, as estimated on TTE or determined from the symptomatology.

The reasons for our use of pulmonary artery catheter:

Transthoracic echocardiogram may overestimate the degree of PH in the pregnant patient.\[[@ref9]\] In our series, 8 peripartum PAC were used. In 4 of these patients measured PAP were lower than estimated, which helped simplify subsequent management. Three of these patients underwent subsequent uneventful vaginal delivery, with no significant change in the hemodynamicsWe have found that the central venous pressure (CVP) and CO are the useful parameters to plan hemodynamic decisions. The measured PAP is indicative of disease severity; however, they are CO dependent. We found that CVP and CO are the most useful combination of measures for clinical management. A rise in CVP and reduction in CO reflect deterioration in right ventricular function, which can manifest as a drop in pulmonary pressures. If PAP was being considered in isolation of the CVP and CO, this could be misinterpreted as an improvement in the patient\'s condition rather than the harbinger of right heart failure. There are risks involved in PAC insertion (arrhythmia, pulmonary artery rupture) but the benefit of monitoring all three parameters, (CO, CVP and PAP) in determining the timing of interventions and management is invaluable in our experience. In future CVP and noninvasive CO methods may reduce the use of the PAC. Transesophageal echocardiogram was used in one patient to guide intraoperative management and is obviously a modality that we will use more into the future.

CONCLUSION {#sec1-5}
==========

Pulmonary hypertension is a rare and serious condition in pregnancy with a tendency to rapid deterioration in severe cases. Early recognition and medical management is helpful and can direct obstetric and anesthetic management. Multidisciplinary management and planning are essential. TTE is diagnostic and gives us information for risk stratification. It is also a monitor of right heart function, and the use of exercise testing may have some outcome predictive value. Mild PH appears to be low-risk; however, monitoring with TTE is essential should the disease progress or they become symptomatic. Epidural analgesia and anesthesia for labor and operative delivery seems to be an acceptable choice. General anesthetic is safe and is the management of choice in the emergent or unstable cases. PAC is invasive, however, provides useful and accurate information if the correct CVP and CO are assessed. The risks versus benefit of PAC should be considered before insertion, and newer noninvasive or semi-invasive modalities may now be more appropriate. Secondary PH results in higher morbidity and mortality, in particular, older the age higher the maternal morbidity and mortality.
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